These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 32450480)
1. Sustained heavy drinking over 25 years is associated with increased N-terminal-pro-B-type natriuretic peptides in early old age: Population-based cohort study. Britton A; O'Neill D; Kuh D; Bell S Drug Alcohol Depend; 2020 Jul; 212():108048. PubMed ID: 32450480 [TBL] [Abstract][Full Text] [Related]
2. Evidence for a Direct Harmful Effect of Alcohol on Myocardial Health: A Large Cross-Sectional Study of Consumption Patterns and Cardiovascular Disease Risk Biomarkers From Northwest Russia, 2015 to 2017. Iakunchykova O; Averina M; Kudryavtsev AV; Wilsgaard T; Soloviev A; Schirmer H; Cook S; Leon DA J Am Heart Assoc; 2020 Jan; 9(1):e014491. PubMed ID: 31847661 [TBL] [Abstract][Full Text] [Related]
3. The minimal informative monitoring interval of N-terminal pro-B-type natriuretic peptide in patients with stable heart failure. Dai Z; Asano T; Takahashi O; Komiyama N; Ohde S BMC Cardiovasc Disord; 2020 Jun; 20(1):262. PubMed ID: 32487160 [TBL] [Abstract][Full Text] [Related]
4. N-Terminal Pro-Brain Natriuretic Peptide and Heart Failure Risk Among Individuals With and Without Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Ndumele CE; Matsushita K; Sang Y; Lazo M; Agarwal SK; Nambi V; Deswal A; Blumenthal RS; Ballantyne CM; Coresh J; Selvin E Circulation; 2016 Feb; 133(7):631-8. PubMed ID: 26746175 [TBL] [Abstract][Full Text] [Related]
5. Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). Bhatt AS; Cooper LB; Ambrosy AP; Clare RM; Coles A; Joyce E; Krishnamoorthy A; Butler J; Felker GM; Ezekowitz JA; Armstrong PW; Hernandez AF; O'Connor CM; Mentz RJ J Am Heart Assoc; 2018 Feb; 7(3):. PubMed ID: 29431103 [TBL] [Abstract][Full Text] [Related]
6. SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF): early detection of chronic heart failure in the workplace. Boffa U; McGrady M; Reid CM; Shiel L; Wolfe R; Liew D; Campbell DJ; Stewart S; Krum H Aust Health Rev; 2017 May; 41(2):121-126. PubMed ID: 27096227 [TBL] [Abstract][Full Text] [Related]
7. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population. Suthahar N; Meijers WC; Ho JE; Gansevoort RT; Voors AA; van der Meer P; Bakker SJL; Heymans S; van Empel V; Schroen B; van der Harst P; van Veldhuisen DJ; de Boer RA Eur J Heart Fail; 2018 Aug; 20(8):1205-1214. PubMed ID: 29855124 [TBL] [Abstract][Full Text] [Related]
8. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction. Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760 [TBL] [Abstract][Full Text] [Related]
9. N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) Measurements Until a 30% Reduction Is Attained During Acute Decompensated Heart Failure Admissions and Comparison With Discharge NT-proBNP Levels: Implications for In-Hospital Guidance of Treatment. Stienen S; Salah K; Dickhoff C; Carubelli V; Metra M; Magrini L; Di Somma S; Tijssen JP; Pinto YM; Kok WE J Card Fail; 2015 Nov; 21(11):930-4. PubMed ID: 26216495 [TBL] [Abstract][Full Text] [Related]
10. Combining the use of amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the prognosis of hospitalized heart failure patients. Wang Y; Zhang R; Huang Y; Zhai M; Zhou Q; An T; Huang Y; Zhao X; Tian P; Zhang Y; Zhang J Clin Chim Acta; 2019 Apr; 491():8-14. PubMed ID: 30594544 [TBL] [Abstract][Full Text] [Related]
11. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score. Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457 [TBL] [Abstract][Full Text] [Related]
12. The Molar Ratio of N-terminal pro-B-type Natriuretic Peptide/B-type Natriuretic Peptide for Heart Failure-related Events in Stable Outpatients with Cardiovascular Risk Factors. Suzuki S; Sugiyama S Intern Med; 2018 Sep; 57(18):2621-2630. PubMed ID: 29709934 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure: the Copenhagen heart failure risk study. Gaborit FS; Kistorp C; Kümler T; Hassager C; Tønder N; Iversen K; Hansen PM; Kamstrup PR; Faber J; Køber L; Schou M Biomarkers; 2020 May; 25(3):248-259. PubMed ID: 32126847 [No Abstract] [Full Text] [Related]
14. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. Alehagen U; Dahlström U; Rehfeld JF; Goetze JP J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592 [TBL] [Abstract][Full Text] [Related]
15. N-Terminal Pro-B-Type Natriuretic Peptide-Guided Therapy in Chronic Heart Failure Reduces Repeated Hospitalizations-Results From TIME-CHF. Davarzani N; Sanders-van Wijk S; Karel J; Maeder MT; Leibundgut G; Gutmann M; Pfisterer ME; Rickenbacher P; Peeters R; Brunner-la Rocca HP J Card Fail; 2017 May; 23(5):382-389. PubMed ID: 28232046 [TBL] [Abstract][Full Text] [Related]
16. NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Stienen S; Salah K; Moons AH; Bakx AL; van Pol P; Kortz RAM; Ferreira JP; Marques I; Schroeder-Tanka JM; Keijer JT; Bayés-Genis A; Tijssen JGP; Pinto YM; Kok WE Circulation; 2018 Apr; 137(16):1671-1683. PubMed ID: 29242350 [TBL] [Abstract][Full Text] [Related]
17. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP; Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403 [TBL] [Abstract][Full Text] [Related]
18. N-terminal pro-brain natriuretic peptide is a useful marker to identify latent heart failure patients in older adults in a rural outpatient clinic. Hamagawa K; Kubo T; Nishimura K; Baba Y; Hirota T; Yamasaki N; Kitaoka H Geriatr Gerontol Int; 2017 Oct; 17(10):1648-1653. PubMed ID: 27860152 [TBL] [Abstract][Full Text] [Related]
19. Urinary N-terminal pro-B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population: the Hisayama Study. Yamasaki K; Hata J; Ide T; Nagata T; Sakata S; Yoshida D; Honda T; Hirakawa Y; Nakano T; Kitazono T; Tsutsui H; Ninomiya T Environ Health Prev Med; 2021 Apr; 26(1):47. PubMed ID: 33845756 [TBL] [Abstract][Full Text] [Related]
20. The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. Kube J; Ebner N; Jankowska EA; Rozentryt P; Cicoira M; Filippatos GS; Ponikowski P; Doehner W; Anker SD; von Haehling S Int J Cardiol; 2016 Sep; 219():84-91. PubMed ID: 27288971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]